

AD _____

Award Number: DAMD17-02-1-0639

TITLE: Modulation of Ras Signaling by NF1 and CRKL in
Development

PRINCIPAL INVESTIGATOR: Akira Imamoto, Ph.D.

CONTRACTING ORGANIZATION: University of Chicago
Chicago, Illinois 60637

REPORT DATE: June 2003

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20031028 142

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE June 2003	3. REPORT TYPE AND DATES COVERED Annual (1 Jun 2002 - 31 May 2003)	
4. TITLE AND SUBTITLE Modulation of Ras Signaling by NF1 and CRKL in Development			5. FUNDING NUMBERS DAMD17-02-1-0639	
6. AUTHOR(S) Akira Imamoto, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Chicago Chicago, Illinois 60637 E-Mail: aimamoto@uchicago.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES Original contains color plates: All DTIC reproductions will be in black and white.				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 Words) Mutations in the NF1 gene are the genetic basis of neurofibromatosis type I, a common genetic disorder which predisposes the patient to neoplasia in the peripheral nervous system as well as other tissues. The NF1 gene encodes a protein called neurofibromin that negatively regulates the small G-protein Ras. Abnormal activation of Ras can cause sustained cell survival and growth in some cells. Ras and other small G-proteins like it are believed to relay critical messages from the cell's environment to the cell nucleus where this information is processed. Crkl (Crk-like) encodes an adapter protein that has been implicated in bridging such messages to small G-proteins like Ras. We have proposed to study the biological role of Crkl during development in conjunction with NF1 and to determine the role of Crkl in regulation of Ras signaling.				
14. SUBJECT TERMS No Subject Terms Provided			15. NUMBER OF PAGES 19	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

Table of Contents

Cover.....	1
SF 298.....	2
Table of Contents.....	3
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	8
Reportable Outcomes.....	8
Conclusions.....	8
References.....	8
Appendices.....	10

(contains unpublished data)

Principal Investigator: Imamoto, Akira

Introduction

The Ras pathway has been a focus of research to understand how proliferation, survival, and differentiation are regulated in the cell. The Neurofibromatosis Type I gene (*NF1*) encodes a GTPase-activating protein (GAP) called neurofibromin that negatively regulates the small G-protein Ras. Therefore, unregulated Ras activity has been implicated in neurofibromatosis type I. *Crk-Like* (*Crkl*) encodes an adapter protein that links tyrosine kinase substrates to guanine nucleotide exchange factors (GEFs) for small G-proteins such as Ras. Although broadly expressed, *Crkl* is concentrated in neural crest derivatives during mouse development. Interestingly, overall phenotypes of *Nf1*^{-/-} and *Crkl*^{-/-} mouse embryos are similar. We propose to study *Crkl*^{-/-} cells and embryos in combination with *Nf1* in order to shed light onto the mechanisms by which Ras pathway modulates cell proliferation, survival, and differentiation.

Body

Specific Aim 1: To determine the developmental mechanism underlying defects in *Crkl*^{-/-} embryos and to investigate genetic interactions between *Nf1* and *Crkl* during development.

Task 1-a. Assess cell proliferation and apoptosis in neural crest derived and other tissues affected in *Crkl*^{-/-} embryos (months 1-6).

There has been unexpected delay in genetic crosses due to breeding problems in the animal facility. Although the exact cause is still unknown, this problem has been recently solved by changing the light cycle (12/12 to 14/10) and rodent feed to the NIH31-modified formula. Due to this delay, however, we are still collecting experimental data regarding cell proliferation and death in neural crest and non-neural crest compartments in *Crkl*^{-/-} embryos in combination with this technique.

As proposed, we have successfully marked the neural crest derivatives by combination of *Wnt1::Cre* and *R26R* Cre reporter strains (Fig. 1). We have noted that neural crest cells migrate into pharyngeal arches and the conotruncus of the heart in *Crkl*^{-/-} embryos (not




Fig. 1 Distribution of neural crest derivatives in an E10.5 mouse embryo. (A) *Wnt1Cre/+;R26R/+* compound heterozygous embryo (wild type for *Crkl*) stained with Salmon-gal. The dotted line approximates the plane of the histological sections (6 mm thickness) shown in (B-E). Embryos were obtained from *W-Cre/+;Crkl*^{-/-} X *R26R/R26R;Crkl*^{-/-} timed mating as outlined in Fig. 8. No background staining was found in *R26R/+* littermate controls without the *W-Cre* transgene (not shown). (B) Histological section at a low magnification (4x objective). da, dorsal aorta; drg, dorsal root ganglia; nt, neural tube. (C) Pharyngeal arch arteries 3, 4, and 6 are surrounded by neural crest mesenchyme (10x objective). as, aortic sac; t, trachea and the surrounding splanchnic mesoderm; p3 and p4, pharyngeal pouches 3 and 4. (D) Truncus (tr) of the heart. Note the onset of septation of the truncus by dorsoventrally opposing expansions of neural crest mesenchyme (arrows). (E) Conus (co) and ventricle (vt) of the heart. Note that neural crest mesenchyme localizes laterally in the conus (arrows). Consistent with the report from the Sucov group, neural crest cells already populate the conotruncus at this stage whereas some studies estimated E11.5 to be the timing of migration.

(contains unpublished data)

Principal Investigator: Imamoto, Akira

shown). We are accumulating the number of embryos to substantiate this observation.

Task 1-b. Analyze chimeric animals for cell autonomous defects (months 6-18)

This task has been delayed due to the breeding problem mentioned above.

Task 1-c. Analyze embryos heterozygous or homozygous for mutation in both *Nf1* and *Crkl* (months 12-18)

We have started *Nf1* and *Crkl* genetic cross. We are currently accumulating compound heterozygotes in order to perform timed mating.

Specific Aim 2: To characterize proliferation, differentiation, and survival of *Crkl*^{-/-} neural crest cells in response to neurotrophic factors and to examine Ras activity in these cells

Task 2-a. Assess cell proliferation, differentiation, and survival of *Crkl*^{-/-} neural crest cells (and wild type controls) in response to neurotrophic factors (months 18-24)

This task was originally planned in year 2. As we experienced the breeding problem mentioned above, we started our analysis in this task in year 1.

Nerve growth factor (NGF) and fibroblast growth factor (FGF) are neurotrophic factors critical for tissue culture of neural crest cells¹. We have found that while initial outgrowth of *Crkl*^{-/-} neural crest cells from the hindbrain is comparable to that of wild type cells, *Crkl*^{-/-} cells respond poorly to FGF. Unfortunately, this makes it difficult to use neural crest cells for detailed analysis (as they rely on FGF). We have therefore characterized impaired FGF signaling pathways in mouse embryonic fibroblasts (MEFs) obtained from wild type and *Crkl*^{-/-} embryos as summarized below.

Among many FGFs expressed during mammalian development, recent studies from other laboratory have shown that *Fgf8* hypomorph mutations result in phenotypes similar to *Crkl*^{-/-} embryos^{2,3}. Defects were found in *Fgf8*-induced cell proliferation and migration in *Crkl*^{-/-} cells, although *Fgf8* induced proliferation only at high concentrations in MEFs (not shown). Since *Crkl*^{-/-} MEFs still express *Crk* at a level comparable to wild type MEFs⁴, *Fgf8* signaling appears to rely specifically on *Crkl*.




Fig. 2 *Crkl* is required for sustained *Erk* activation induced by *Fgf8*. **a** and **b**, Activated *Erk1* and *Erk2* (p44/p42) were detected by phospho-specific *Erk* antibody in Western blots. **a**, Cell lysates were prepared 10 min after incubation with *Fgf8b* at various concentrations. The lower panel shows total protein levels of *Erk1* and *Erk2*. **b**, Cell lysates were prepared at the time indicated after incubation with 20 ng/ml *Fgf8b*. Reblotting with anti-*Erk* antibody indicated equal levels of total *Erk1* and *Erk2* proteins in the samples (not shown). The lower panel shows a plot of phospho-*Erk* levels in time-course (the average of two independent experiments). Values are fold activation relative to the 0-min level of wild type cells.

(contains unpublished data)

Principal Investigator: Imamoto, Akira

To begin our investigation of Fgf8-induced signaling, we have determined the dose-response relationship using activation of the MAP kinases Erk1 and Erk2 as a readout for Ras activation (Fig. 2a). Fgf8 induced a significant increase in Erk activation in the range of 0.2-40 ng/ml in wild type MEFs, whereas Fgf8 was capable of inducing Erk activation only at high concentrations (20-40 ng/ml) in *Crkl*^{-/-} MEFs. We noted that *Crkl*^{-/-} MEFs required approximately 10-fold higher concentration (20 ng/ml) to induce the level of Erk activation equivalent to that of 2 ng/ml Fgf8 in wild type cells. We also noted that the basal level of Erk phosphorylation (without Fgf8) was elevated in *Crkl*^{-/-} cells approximately 2 fold compared to that of wild type cells.

While many growth factors such as EGF (epidermal growth factor) and PDGF (platelet-derived growth factor) can induce "transient" activation of Erk, "sustained" Erk activation is considered a hallmark of FGF signaling. We therefore determined the time-course of Erk activation induced by Fgf8 in MEFs. Erk activation induced by Fgf8 became detectable as early as 5 min, and peaked at 10 min in wild type cells (Fig. 2b). Although it slightly declined, activation persisted for at least 2 hours. By contrast, in *Crkl*^{-/-} cells, Fgf8 induced Erk activation in 10 minutes to a modest degree compared to the robust response in wild type cells. Interestingly, Erk activation in *Crkl*^{-/-} cells appeared to be only transient and the level of activated Erk came down to the basal level by approximately 1 hour (Fig. 2b). Add back experiments with various levels of *Crkl* re-expressed in *Crkl*^{-/-} cells indicate that the peak of Erk activation induced by Fgf8 correlates positively with the *Crkl* protein level, while the basal level of Erk phosphorylation inversely correlates with the level of *Crkl* protein expressed in the cell (not shown). Thus, *Crkl* can enhance the magnitude of Fgf8-induced response both by lowering the basal level and by elevating the peak (not shown).

We next examined tyrosine phosphorylation of cellular proteins at various times after Fgf8 stimulation (Fig. 3a). While many proteins were constitutively tyrosine-phosphorylated, Fgf8 induced phosphorylation in a protein with an apparent molecular mass of 90 kD as early as 5-10 min in wild type cells (arrowhead, Fig. 3a). This phosphorylation persisted at least for 2 hours. By contrast, in *Crkl*^{-/-} cells, this protein became phosphorylated at 10 min to a lesser degree compared to that in wild type cells, and tyrosine phosphorylation declined almost to the




Fig. 3 *Crkl* is required for sustained *Frs2* tyrosine phosphorylation induced by Fgf8. **a**, Upper panel is an anti-phosphotyrosine blot using total cell lysates (pY blot). Cell lysates were prepared at the time indicated after incubation with 20 ng/ml Fgf8b. Arrowhead indicates the position of a 90 kD protein phosphorylated after Fgf8 incubation. The blot was re-probed with anti-Frs2 (lower panel). Gray arrow indicates the position that corresponds to the arrowhead in the pY blot. **b**, Anti-phosphotyrosine blot of immunoprecipitated Frs2. Cell lysates were prepared 10 min after incubation. Lanes marked as "+ Crkl 1, 2, and 3" are samples from *Crkl*^{-/-} cells that express re-introduced *Crkl* at the level of 2.0, 1.2, and 0.1 fold compared to the endogenous *Crkl* level in wild type cells, respectively (*Crkl* protein levels not shown).

basal level by 60 min. Interestingly the time-course of tyrosine phosphorylation on this protein correlates closely to that of Erk activation shown in Fig. 2. Re-probing the same membrane with anti-Frs2 antibody detected broad electrophoretic mobility of this protein (Fig. 3a), due likely to phosphorylation on tyrosine and threonine residues as reported previously⁵. A slow migrating form of Frs2 (gray arrow) exactly overlapped with the position of the 90 kD tyrosine-phosphorylated protein in the same blot (Fig. 3a). Further immunoprecipitation-Western analysis confirmed that this protein is indeed Frs2. In experiments in which a *Crkl* transgene was re-expressed in *Crkl*^{-/-} cells, the level of Frs2 tyrosine phosphorylation correlated with Crkl protein levels expressed in the cell (Fig. 3b). Overexpression of *Crkl* at about 2 fold (+ Crkl lane 1) enhanced Frs2 phosphorylation 1.5 fold compared to wild type cells in response to Fgf8, while the level of Frs2 phosphorylation in *Crkl*^{-/-} cells was approximately 40% of that of wild type cells (Fig. 3b). It has been shown that Frs2 is critical for Erk activation as well as cell proliferation and migration in response to FGF⁶. It is therefore possible that defects of *Crkl*^{-/-} cells are due at least partly to their poor ability to induce Frs2 tyrosine phosphorylation in response to Fgf8.

In addition, we noted differences between *Crkl*^{-/-} and wild type cells at around 150-160 kD (bracket) and 70 kD (asterisk) (Fig. 3a). Tyrosine phosphorylation of a protein or proteins with 150-160 kD molecular mass was elevated in response to Fgf8 in wild type cells, whereas *Crkl*^{-/-} cells did not increase tyrosine phosphorylation in this molecular mass range. Tyrosine phosphorylation of another protein with 70 kD molecular mass appear to be reduced in response to Fgf8 in wild type cells due possibly to dephosphorylation or mobility shift, which inversely correlates with that of Frs2 (arrowhead). On the other hand, this protein remained heavily phosphorylated in *Crkl*^{-/-} cells. We are currently investigating the identities of these proteins.

Focal adhesion signaling is an important part of growth factor signaling⁷⁻⁹. Crkl may play an important role in focal adhesion signaling. We therefore determined whether Fgf8 affects subcellular localization of Crkl as well as Frs2 in wild type MEFs (Fig. 4). Crkl diffusely distributes in cytosolic compartments in quiescent MEFs (Fig. 4, 0-min). Upon stimulation with Fgf8b, a subset of Crkl translocates to focal adhesions (Fig. 4, green arrowheads). Thus, it is possible that Crkl focal adhesion translocation may trigger pathways that may affect Fgf8 signaling. It should be noted that translocation of Crkl to focal adhesions *per se* can activate Rac and Cdc42, but not Ras (see appended manuscript)⁴. It remains to be determined that activation of these small G-proteins may cooperate with the Ras pathway upon Fgf8 stimulation.




Fig. 4 Subcellular localization of *Crkl* and *Frs2* after *Fgf8* stimulation. *Crkl* and *Frs2* were localized by immunofluorescent staining of cells before and 10 min after stimulation with Fgf8b (20 ng/ml). Green arrowheads show some localization of Crkl at focal adhesions. Blue and Red arrowheads point Crkl and Frs2 localization, respectively in unknown subcellular structure. White arrowheads indicate that these proteins co-localize. Merged images indicate Crkl and Frs2 distribution in green and red, respectively (blue color is DAPI nuclear staining).

Following Tasks will be initiated in the upcoming years:

Task 2-b. Assess real-time activity and signaling of small G-proteins in *Crkl*^{-/-} and wild type neural crest cells (months 24-30)

Task 2-c. Assess phenotypic rescue of defects in *Crkl*^{-/-} neural crest cells by downstream mediators of *Crkl* and *Ras* (months 24-36).

Key Research Accomplishments

We have made the following key observations:

- Neural crest cells migrate and contribute initially to pharyngeal arches in *Crkl*^{-/-} embryos. Thus, defects in *Crkl*^{-/-} embryos are due likely to short-distance or local problems.
- *Crkl* is essential for *Fgf8* signaling.
- *Crkl* plays a role in *Fgf8*-induced phosphorylation of *Frs2* and sustained activation of the MAP kinases *Erk1* and *Erk2*.
- *Crkl* translocates to focal adhesions upon stimulation with *Fgf8*.
- Translocation of *Crkl* to focal adhesions *per se* can activate *Rac1* and *Cdc42*, but not *Ras*.

Reportable Outcomes

Following manuscript (published) includes our studies in which we found that *Crkl* can modulate GTP-loading of *Rac1* and *Cdc42*.

- Li, L., Guris, D. L., Okura, M., and **Imamoto, A.** Translocation of *Crkl* to Focal adhesions Mediates Integrin-induced Migration Downstream of *Src* Family Kinases. *Mol. Cell. Biol.* **23**, 2883 – 2892 (2003).

Conclusions

We have found that *Crkl* dependent signaling pathways play important roles in regulation of small G-proteins such as *Ras*, *Rac1*, and *Cdc42*. Our current work will elucidate the function of *NF1*, a negative regulator of *Ras*. Since the *Ras* pathway is crucial for *Fgf8* signaling and defects in *Nf1* and *Crkl*-deficient mice are similar, we anticipate some interaction of these genes during development.

References

1. Rao, M.S. & Anderson, D.J. Immortalization and controlled in vitro differentiation of murine multipotent neural crest stem cells. *J Neurobiol* **32**, 722-46 (1997).
2. Frank, D.U. et al. An *Fgf8* mouse mutant phenocopies human 22q11 deletion syndrome. *Development* **129**, 4591-4603 (2002).
3. Abu-Issa, R., Smyth, G., Smoak, I., Yamamura, K.I. & Meyers, E.N. *Fgf8* is required for pharyngeal arch and cardiovascular development in the mouse. *Development* **129**, 4613-4625 (2002).
4. Li, L., Guris, D.L., Okura, M. & Imamoto, A. Translocation of *Crkl* to focal adhesions mediates integrin-induced migration downstream of *Src* family kinases. *Mol Cell Biol* **23**, 2883-92 (2003).

(contains unpublished data)

Principal Investigator: Imamoto, Akira

5. Lax, I. et al. The docking protein FRS2alpha controls a MAP kinase-mediated negative feedback mechanism for signaling by FGF receptors. *Mol Cell* **10**, 709-19 (2002).
6. Hadari, Y.R., Gotoh, N., Kouhara, H., Lax, I. & Schlessinger, J. Critical role for the docking-protein FRS2 alpha in FGF receptor-mediated signal transduction pathways. *Proc Natl Acad Sci U S A* **98**, 8578-83. (2001).
7. Sieg, D.J. et al. FAK integrates growth-factor and integrin signals to promote cell migration. *Nat Cell Biol* **2**, 249-56 (2000).
8. Ivankovic-Dikic, I., Gronroos, E., Blaukat, A., Barth, B.U. & Dikic, I. Pyk2 and FAK regulate neurite outgrowth induced by growth factors and integrins. *Nat Cell Biol* **2**, 574-581 (2000).
9. Miyamoto, S., Teramoto, H., Gutkind, J.S. & Yamada, K.M. Integrins can collaborate with growth factors for phosphorylation of receptor tyrosine kinases and MAP kinase activation: roles of integrin aggregation and occupancy of receptors. *J Cell Biol* **135**, 1633-42. (1996).

Translocation of CrkL to Focal Adhesions Mediates Integrin-Induced Migration Downstream of Src Family Kinases

Leiming Li,^{1,2} Deborah L. Guris,² Masaya Okura,^{2†} and Akira Imamoto^{1,2,3*}

Committees on Cell Physiology¹ and Cancer Biology³ and The Ben May Institute for Cancer Research and Center for Molecular Oncology,² The University of Chicago, Chicago, Illinois 60637

Received 27 November 2002/Returned for modification 9 January 2003/Accepted 30 January 2003

The adapter protein Crk-Like (CrkL) can associate with the Src substrate p130^{Cas} (Cas). The biological role of CrkL downstream of Cas, however, has been largely obscure. Consistent with the ability of CrkL to biochemically associate with Cas, we found that Src triggers translocation of CrkL to focal adhesions (FAs) in a manner dependent on Cas. Forced localization of CRKL to FAs (FA-CRKL) by itself was sufficient to induce activation of Rac1 and Cdc42 and rescued haptotaxis defects of mouse embryonic fibroblasts (MEFs) lacking Src, Yes, and Fyn, three broadly expressed Src family members required for integrin-induced migration. Consistent with Rac1 activation, FA-CRKL induced cotranslocation of a Rac1 activator, Dock1, to focal adhesions. These results therefore indicate a role for CrkL in mediating Src signaling by activating small G proteins at focal adhesions. Furthermore, MEFs lacking CrkL show impaired integrin-induced migration despite expression of a closely related protein, Crk-II, in these cells. These results therefore provide formal evidence that CrkL plays a specific role in integrin-induced migration as a downstream mediator of Src.

Crk-Like (CrkL) is a member of the Crk adapter protein family, consisting of one SH2 and two SH3 domains. Among many proteins known to associate with CrkL (and Crk), p130^{Cas} (Cas) has been implicated in Src signaling (36). In normal cells, Cas is distributed predominantly in the cytosol with a small fraction localized to focal adhesions where interaction of the cell with the extracellular matrix takes place through heteromeric transmembrane proteins known as integrins (31). Activated Src induces translocation of Cas to podosome-like abnormal focal adhesions (31). It has been shown that Cas plays an essential role in Src signaling since mouse embryonic fibroblasts (MEFs) lacking Cas are resistant to activated Src-induced anchorage-independent growth (19). In normal cells, focal adhesion kinase (Fak) and Src cooperate to phosphorylate Cas upon integrin binding to the extracellular matrix (35, 44). While another Src family member, Fyn, also associates with Cas (37), overall tyrosine phosphorylation of Cas largely relies on Src (14, 47).

Consistent with the implicated role of Src family kinases in integrin-mediated signaling, MEFs lacking Src, Yes, and Fyn—the three most widely expressed members of the Src family (SYF cells)—display severe reduction in global tyrosine phosphorylation of many Src substrates, including Cas, that the extracellular matrix protein fibronectin induces in normal cells (25). Whereas SYF cells are capable of migrating toward platelet-derived growth factor, they show impaired motility toward fibronectin (haptotaxis). The recent finding that catalytic activity of Src is necessary for proper haptotaxis provides further evidence that involvement of Src substrates is essential in this process (7). Since Cas-deficient cells show similar motility de-

fects (18), these findings suggest that a pathway or pathways downstream of Cas mediate Src-dependent adhesion signaling induced by integrins.

As Cas is a major CrkL binding protein, we explore a role for CrkL in integrin-induced signaling downstream of Src in the present work. We show that one important function of Src family kinases is to induce translocation of CrkL to focal adhesions through Cas. By taking advantage of MEFs isolated from CrkL-deficient mice (12), we show that CrkL plays an essential role in integrin signaling. Since Crk and CrkL can associate with similar if not identical sets of proteins *in vitro*, the functions of these proteins have been thought to be largely overlapping (10). On the other hand, whereas Crk-II, a broadly expressed isoform of the *Crk* gene most closely related to CrkL, is not transforming in fibroblasts (28), overexpression of CrkL transforms cells *in vitro* and *in vivo* (17, 41), thus suggesting a functional difference between these two closely related proteins. Crk-II has been implicated in the pathway from CED-2 to CED-10 originally identified in *Caenorhabditis elegans* due to close similarity between CED-2 and Crk-II (33). Our studies described in this paper provide formal evidence that CrkL, rather than Crk-II, plays an essential role in linking integrin signaling to this evolutionally conserved pathway downstream of Src and Cas.

MATERIALS AND METHODS

Subcellular targeting constructs of CRKL. Focal adhesion-targeted CRKL (FA-CRKL) was generated by inserting in frame a human CRKL coding sequence into the *Bam*HI site immediately 5' of the translation start site of green fluorescent protein (GFP)-LIM in a modified pGreenLantern-1 expression vector (27). The stop codon of CRKL cDNA was replaced with a *Bgl*II site by PCR mutagenesis by using *Pfu* DNA polymerase (Stratagene) prior to subcloning. The *Cf*:10I-*Cf*:10I (nucleotides 560 to 752), *Dra*I-*Alu*I (nucleotides 941 to 1049), or *Ava*III-*Ba*II (nucleotides 1127 to 1327) fragment was removed to generate CRKL(ΔSH2), CRKL(ΔSH3n), or CRKL(ΔSH3c), respectively. The number of nucleotides referred here corresponds to that of human CRKL (GenBank accession no. X59656). Full-length CRKL and CRKL(K39) cDNA fragments were gifts from Brian J. Druker (16). Mitochondrial surface-targeted CRKL (CRKL-

* Corresponding author. Mailing address: The University of Chicago, 924 E. 57th St., JFK-R316, Chicago, IL 60637. Phone: (773) 834-1258. Fax: (773) 702-4394. E-mail: aimamoto@uchicago.edu.

† Present address: Department of Oral and Maxillofacial Surgery, Osaka University, Suita, Osaka 560, Japan.

GFP-mito) was generated by fusing CRKL-GFP (without a stop codon) in frame with the transmembrane region of the *Listeria* protein ActA (residues 612 to 633), which directs the fusion protein to the outer surface of mitochondria (a gift from Frank B. Gertler) (2). For permanent expression, vectors were linearized and transfected into cells by electroporation or using Effectene (Qiagen) as described in the manufacturer's protocol. In some experiments, retrovirus was used for permanent expression as described below. For transient expression, intact plasmids were transfected into cells using Effectene.

MEFs. Primary MEFs were isolated from embryonic-day-12.5 *Crkl*^{-/-} and wild-type embryos. Some cells used in this study were spontaneously immortalized by regular splitting according to the 3T3 protocol. To reintroduce CRKL into *Crkl*^{-/-} cells, cells were electroporated with a linearized pBABE puro CRKL plasmid for permanent expression. SYF cells and their Src-expressing control cells were gifts from Philippe Soriano (25). MEFs lacking Cas and their Cas-expressing control cells were gifts from Hisamaru Hirai (18). Activated mouse Src in which the regulatory tyrosine residue is replaced with a phenylalanine (SrcY529F) (27) was introduced into *Crkas*^{-/-} (Cas-deficient) cells and their control cells by pBABE puro SrcY529F retrovirus as prepared below. MEFs lacking Csk as well as Src or Fyn were reported previously (21, 46). Primary MEFs were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (HyClone). All other immortalized cells were maintained in DMEM supplemented with 7.5% Cosmic calf serum (HyClone).

Retroviral expression. NIH 3T3 cells or SYF cells that express FA-GFP, FA-CRKL, or FA-CRKL(ΔSH3n) were generated by retrovirus infection by using a pBABE puro retroviral vector (30). Ecotropic retrovirus was produced by transient transfection of φNX cells (a gift from G. P. Nolan) with the viral vector as previously described (23). One to 2 days after infection, cells infected with pBABE puro retrovirus were selected with 2 μg of puromycin/ml.

Immunofluorescence staining. Cells were plated onto fibronectin-coated glass coverslips in a 24-well tissue culture plate and fixed after an indicated period of culture. F-actin was stained with Alexa 594-conjugated phalloidin as previously described (27). Subcellular localization of paxillin, vinculin, and Dock1 was determined with antipaxillin (BD Biosciences) monoclonal antibody, antivinculin (Sigma) monoclonal antibody, or anti-Dock1 polyclonal antibodies (Santa Cruz Biotechnology) followed by Alexa 594 or Cy5-conjugated anti-mouse immunoglobulin G. Subcellular localization of multiple fluorophores (including GFP) was recorded by using a Zeiss axiovert microscope equipped with a charge-coupled device camera.

Cell migration. Modified Boyden chamber assays were performed to assess cell motility as previously described by using a polyethylene terephthalate (PET) tissue culture insert with 8-μm pores (BD Biosciences) (25). Haptotaxis assays were performed with PET inserts, of which only the lower surface was coated with 5 μg of fibronectin/ml for 2 h. Chemotaxis and chemokinesis assays were performed with PET inserts, of which both the upper and lower sides were coated with fibronectin. For haptotaxis assays, both upper and lower chambers were filled with serum-free DMEM. For chemotaxis and chemokinesis assays, the agent was added to either lower or upper chamber, respectively. After 16 h of serum starvation, cells were harvested with trypsin-EDTA, which was then neutralized by trypsin inhibitor (Sigma). Cells were further diluted in serum-free DMEM (with 1× insulin-transferrin-sodium selenite medium supplement for SYF cells) and plated into the upper chamber. After 3 h, cells were fixed in neutral buffered formalin and those remaining on the upper surface were removed by cotton swabs. The membrane was removed by scalpel, and cells on the lower surface were stained with 4',6'-diamidino-2-phenylindole. The number of cells that had traversed through the pores to the lower surface of the membrane was counted by the ImageJ program (a Java version of NIH Image) in digital images taken under a fluorescent microscope.

Immunoblot and pulldown assays. Cells were lysed in radioimmunoprecipitation assay buffer. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblot analysis were performed according to a standard protocol. Polyclonal anti-Crk-II or anti-CrkL antibodies (Santa Cruz Biotechnology) were used to detect Crk-II or CrkL protein levels. Monoclonal anti-Ras, anti-Rac1 (BD Biosciences), and polyclonal anti-Cdc42 (Santa Cruz Biotechnology) antibodies were used to detect Ras, Rac1, or Cdc42, respectively. After incubation with secondary antibody conjugated with horseradish peroxidase, blots were developed with a chemiluminescent agent (Pierce). The results of each immunoblot were analyzed by the ImageJ program for quantitation with at least two different exposures to avoid over- or underexposure.

Pulldown assays were performed as previously described (51). Briefly, cell lysates in radioimmunoprecipitation assay buffer (400 μg of proteins) were incubated with 20 μg of recombinant glutathione transferase (GST) fusion proteins (GST-Raf1-RBD for GTP-Ras and GST-Pak-RBD for GTP-Rac1 and

GTP-Cdc42) precoupled to glutathione-Sepharose 4B beads (Amersham Pharmacia) at 4°C for 1 h. One-third of precipitated proteins was loaded into each lane to detect GTP-loaded small G proteins bound to the GST fusion protein by immunoblot analysis as described above. To determine the amount of Rac1, Cdc42, or Ras, a total cell lysate containing 10 μg of proteins was loaded into each lane in parallel. Plasmids for GST-Raf1-RBD and GST-Pak-RBD were gifts from Martin Alexander Schwartz and Michiyuki Matsuda, respectively.

RESULTS

Translocation of CrkL to focal adhesions in response to increased activity of Src. While many CrkL binding proteins have been identified, the biological pathways that CrkL mediates in the cell are still obscure. Previous biochemical analysis has shown that CrkL can physically associate with p130^{Cas} (Cas) and paxillin (5, 38, 39). Since Cas and paxillin are substrates of Src family tyrosine kinases *in vivo* (25, 46), elevated activity of Src family kinases may affect subcellular localization of CrkL. To test this possibility, we have examined subcellular localization of CrkL tagged with GFP (CRKL-GFP). CRKL-GFP was diffusely distributed in the cytosol in perinuclear compartments and in the nucleus in quiescent wild-type MEFs (Fig. 1A). In contrast, a subset of CRKL-GFP constitutively colocalized to focal adhesions with paxillin in MEFs lacking a major negative regulator of Src family kinases, Csk, in which multiple Src members are therefore activated (21) (Fig. 1A). Similar results were obtained by staining endogenous CrkL in *Csk*^{-/-} cells (data not shown). On the other hand, CRKL(K39)-GFP, in which the FLVR motif essential for binding to phosphorylated tyrosine residues was mutated to an FLVK sequence, did not localize to focal adhesions in *Csk*^{-/-} cells (Fig. 1A). These results therefore indicate that Src family kinases can induce translocation of CrkL to focal adhesions in a manner dependent on the SH2 domain of CrkL.

To assess relative contributions of Src members to CrkL translocation, we examined subcellular localization of CRKL-GFP in MEFs lacking Src or Fyn as well as Csk (*Src*^{-/-} *Csk*^{-/-} or *Fyn*^{-/-} *Csk*^{-/-}) (46) (Fig. 1A). We found that localization of CRKL-GFP was greatly reduced in *Src*^{-/-} *Csk*^{-/-} cells at focal adhesions, although it was still detectable. On the other hand, *Fyn*^{-/-} *Csk*^{-/-} cells showed accumulation of CRKL-GFP at focal adhesions. Localization of CRKL-GFP in *Src*^{-/-} *Fyn*^{-/-} *Csk*^{-/-} cells was not overtly different from that in *Src*^{-/-} *Csk*^{-/-} cells (not shown). As noted earlier, Cas has been implicated in Src signaling. We therefore examined CrkL localization in Cas-deficient (*Crkas*^{-/-}) cells as well as control cells with reintroduced Cas (*Crkas*^{-/-} + Cas) after overexpression of activated mouse Src (SrcY529F) by retrovirus infection. Whereas CrkL accumulated to abnormal focal adhesions called podosomes in control MEFs expressing SrcY529F, the concentration of CrkL at focal adhesions was diminished in *Crkas*^{-/-} MEFs expressing SrcY529F (Fig. 1B). These results therefore suggest that Src plays a major role in CrkL translocation, dependent largely on the Src substrate Cas, to focal adhesions in embryonic fibroblasts, while other Src family members or potentially other tyrosine kinases may also participate.

Subcellular localization of CrkL in migrating fibroblasts. In the above experiments, translocation of CrkL to focal adhesions was examined in cells in which Src activity was abnormally induced. To address whether translocation of CrkL oc-




FIG. 1. Subcellular localization of CrkL in fibroblasts that express active Src. (A) CRKL-GFP or CRKL(K39)-GFP was transiently expressed in wild-type, *Csk*^{-/-}, *Src*^{-/-}, *Csk*^{-/-}, and *Fyn*^{-/-} *Csk*^{-/-} MEFs as indicated. Localization of the fusion protein was determined by GFP fluorescence. Antipaxillin was used as a marker for focal adhesions. (B) An activated mouse Src (SrcY529F) was permanently expressed in *Crkas*^{-/-} cells and their control cells with reintroduced Cas (*Crkas*^{-/-} + Cas) by pBABE puro retroviral vector. Subcellular localization of endogenous CrkL and vinculin was determined by immunofluorescence staining. F-actin was stained by phalloidin. Arrows indicate aggregation of F-actin, CrkL, and vinculin in podosome-like adhesion structures (overlap of the three colors show large whitish dots).

curs in physiological contexts, we next examined normal fibroblastic cells (Fig. 2). Permissive conditions for migration were generated by scraping cells off from a confluent culture to generate a cell-free zone as used in "wound healing" motility assays. As cells migrated into the cell-free zone, CrkL became

concentrated at the ruffling edge, where F-actin also accumulated (Fig. 2A). In a large subset of migrating cells (approximately 50%), endogenous CrkL localized to focal adhesions in a limited area of the cell (Fig. 2B). Closer examination of CrkL in these focal adhesions showed that CrkL was concentrated in




FIG. 2. Subcellular localization of CrkL in migrating cells. (A to C) Subcellular localization of endogenous CrkL, paxillin, and F-actin. NIH 3T3 cells were plated on glass coverslips coated with fibronectin. Photographs of migrating cells were taken 3 h after generation of the cell-free zone. (A) The upper row shows quiescent NIH 3T3 cells; the lower row shows migrating NIH 3T3 cells. (B) The panel shows focal adhesion localization of CrkL in a large subset of migrating NIH 3T3 cells. (C) A higher magnification of the part of the cell highlighted by a white rectangle in panel B. The images are merged for three components: F-actin, CrkL, and paxillin. The panel at the right shows enlarged focal adhesion structures, where whiteness indicates overlap among F-actin, CrkL, and paxillin.

a region of focal adhesions where paxillin and F-actin overlapped (Fig. 2C). Similar distribution of CrkL within focal adhesions was observed in *Csk*^{-/-} cells as well as in MEFs expressing SrcY529F (not shown). Thus, translocation of CrkL to focal adhesions and F-actin-rich domains normally occurs during migration, although this may be transient.

Translocation of CrkL to focal adhesions rescues motility defects of SYF cells. To explore the role that CrkL plays at focal adhesions, we have generated fusion proteins of CrkL (FA-CRKL) with the LIM domains of paxillin, which are essential for focal adhesion localization (3). Figure 3A illustrates the structures of fusion proteins used in this study. These proteins were further tagged by GFP to aid determination of subcellular location of these proteins. As noted above, Src family kinases (namely, Src, Fyn, and Yes) are essential for phosphorylation of focal adhesion proteins such as Cas and paxillin (25). One possible explanation for impaired haptotaxis toward fibronectin in MEFs lacking Src, Yes, and Fyn (SYF cells) may be the inability of these cells to recruit CrkL to focal adhesions in response to fibronectin-integrin binding. To provide evidence for this hypothesis, we expressed FA-CRKL proteins in SYF cells (Fig. 3B). As expected, expression of FA-CRKL (at a level comparable to that for endogenous CrkL) was sufficient for complementing impaired motility of SYF cells in haptotaxis assays (Fig. 3C; Student two-sample *t* test, $P = 0.004$ compared to SYF cells) to a degree similar to that of control SYF cells in which wild-type Src had been reintroduced. On the other hand, expression of FA-CRKL lacking the SH3n domain had no detectable effect in these assays. These results therefore indicate that localization of CrkL to focal adhesions is sufficient to override the need for

Src family kinases during directional locomotion toward fibronectin (haptotaxis).

CrkL is required for haptotaxis toward fibronectin. To determine whether CrkL is required for cell motility, we then examined MEFs lacking CrkL (*Crkl*^{-/-} cells). Consistent with the effect of FA-CRKL on cell migration, *Crkl*^{-/-} cells showed poor haptotaxis toward fibronectin compared to that of wild-type cells and of control *Crkl*^{-/-} cells in which human CRKL was reintroduced to a level similar to that of wild-type cells (*Crkl*^{-/-} + CRKL) (Fig. 4A and B; Student two-sample *t* test, $P = 0.0001$). Interestingly, however, *Crkl*^{-/-} cells showed normal chemotaxis toward serum (Fig. 4B). These cells also responded normally to serum for chemokinesis (not shown). A CrkL-related protein, Crk-II, was expressed in *Crkl*^{-/-} cells with an elevated level (approximately 1.7-fold) compared to that of wild-type cells or of *Crkl*^{-/-} cells, which express reintroduced CrkL (Fig. 4A). These results therefore indicate that normal haptotaxis requires CrkL, while *Crkl*^{-/-} cells retain the general machinery of cell locomotion, which can be utilized in serum-stimulated migration.

Translocation of CRKL to focal adhesions results in cytoskeletal reorganization. To provide insight into the cellular events that CrkL translocation to focal adhesions can induce, we examined the morphology of NIH 3T3 cells that express FA-CRKL (Fig. 5). The majority of cells (approximately 60%) extended multiple membrane protrusions decorated by fan-shaped lamellipodia with permanent expression of FA-CRKL at a level comparable to that of endogenous CrkL (see Fig. 6A for expression level). Figure 5A presents a severely affected case to emphasize characteristic changes that FA-CRKL can




FIG. 3. Subcellular targeting of CRKL to focal adhesions rescues motility defects of SYF cells. (A) The panel illustrates the structures of fusion proteins used in this study. (B) Immunoblot analysis for endogenous CrkL and FA-CRKL proteins expressed in cells used in panel C. (C) Modified Boyden chamber haptotaxis assay. The number of cells (cells migrated/field) that had traversed to reach the lower surface coated with fibronectin through pores in the insert that separated two chambers was determined 3 h after plating cells into the upper chamber. Error bars indicate the standard deviation of the sample data obtained in four individual microscopic fields under a 40 \times objective lens. Similar results were obtained in three independent experiments.

induce in the cytoskeleton. FA-CRKL localized to focal adhesions as well as to the edge of lamellipodia, where F-actin also accumulated.

To determine the domains of FA-CRKL necessary for this effect, we then transiently expressed mutants of FA-CRKL in NIH 3T3 cells. FA-CRKL(K39) (with an R39K point mutation that disrupts binding of the SH2 domain to phosphotyrosine residues) still induced cytoskeletal reorganization (Fig. 5B), thus suggesting that, while the SH2 domain plays an essential role in translocation of CrkL to focal adhesions (Fig. 1), it may be dispensable in mediating pathways downstream once localized to focal adhesions. It has been noted that some SH2 domains may mediate protein-protein interactions independently of phosphotyrosine (1, 8). Therefore, the point mutation in the SH2 domain of FA-CRKL(K39) may still allow protein-protein interactions independently of phosphotyrosine. However, another SH2 mutant of FA-CRKL in which the SH2 domain was deleted still induced cellular projections containing lamellipodia in a manner similar to that of FA-CRKL or

FA-CRKL(K39) (data not shown). On the other hand, deletion of the SH3n domain from FA-CRKL abolished its ability to induce characteristic protrusions decorated by lamellipodia (Fig. 5B). FA-CRKL(K39+ΔSH3c) in which both the SH2 and SH3c domains were mutated was still capable of inducing cytoskeletal rearrangements (Fig. 5B). Therefore, the SH3n domain appeared to be necessary and sufficient for the effect of FA-CRKL on the cytoskeleton.

While the results mentioned above suggest a role for SH3 binding proteins in cytoskeletal rearrangement at focal adhesions, it is possible that FA-CRKL may sequester SH3 binding proteins from other functional locations important for cytoskeletal organization. We therefore addressed this possibility by targeting of CRKL to another subcellular location, the mitochondrial outer surface with another fusion protein, CRKL-GFP-mito. Unlike FA-CRKL, however, overexpression of CRKL-GFP-mito did not generate membrane protrusions decorated with lamellipodia (Fig. 5C). Therefore, FA-CRKL leads to cytoskeletal reorganization most likely by activation of




FIG. 4. CrkL-deficient cells display haptotaxis defects. (A) Immunoblot analysis for CrkL and Crk-II in MEFs used for panel B. (B) Modified Boyden chamber migration assays. Haptotaxis toward fibronectin was determined as shown in Fig. 3C. Chemotaxis toward serum was determined in an assay similar to the haptotaxis assay except that both sides of the insert were coated with fibronectin with or without fetal bovine serum (10%) (FBS + or -, respectively) included in the lower chamber. Error bars indicate the standard deviation of the sample data obtained in four independent microscopic fields under a 40 \times objective lens. Three independent experiments yielded similar results.

CRKL SH3n binding proteins at focal adhesions rather than by sequestration of SH3 binding proteins.

We then compared the effects of FA-CRKL with that of CRKL-GFP. While CRKL-GFP induced a slight increase in the number of cells with characteristic membrane protrusions compared to GFP alone (11.3 versus 4.6%; Student *t* test, $P = 0.0053$), FA-CRKL was far more effective than was CRKL-GFP (64.3 versus 11.3%; Student *t* test, $P = 0.0011$) by transfecting cells at a high dose of 0.3 $\mu\text{g}/\text{well}$ of plasmid by Effectene (Fig. 5D). Lower doses of CRKL-GFP resulted in no significant increase in the number of cells with lamellipodia, whereas FA-CRKL induced lamellipodia in approximately 58, 37, and 23% of transfected cells at doses of 0.1, 0.04, and 0.015 $\mu\text{g}/\text{well}$ of plasmid, respectively (not shown). Together with the localization control shown in Fig. 5C, these results indicate that focal adhesion localization of CRKL efficiently activates the machinery of cytoskeletal organization. Furthermore, in addition to an increase in the number of cells with lamellipodia, expression of FA-CRKL significantly increased the number of lamellipodia per cell compared to that of control cells (Kolmogorov-Smirnov test for frequency distributions, $P \leq 2.2 \times 10^{-16}$) (Fig. 5E). On the other hand, expression of FA-GFP or FA-CRKL lacking the SH3n domain showed no overt change in the cytoskeleton. These results therefore confirmed that focal adhesion localization of CRKL efficiently leads to cytoskeletal reorganization.

Translocation of CRKL to focal adhesions activates pathways toward Rac1 and Cdc42. In order to provide insight into the molecular mechanism of cytoskeletal changes induced by FA-CRKL, we next examined the state of small G proteins that have been implicated in organization of the actin cytoskeleton.

We found that levels of GTP-loaded (active) Rac1 and Cdc42 in NIH 3T3 cells expressing FA-CRKL were elevated approximately 2.5- and 2.3-fold compared to that of control NIH 3T3 cells, respectively (Fig. 6B). On the other hand, FA-CRKL expression had little effect on levels of GTP-bound Ras. Consistent with these results, expression of a dominant-negative form of either Rac1 (Rac1 N17) or Cdc42 (Cdc42 N17), but not RhoA (RhoA N17) or Ras (Ras N17), inhibited the effect of FA-CRKL on cytoskeletal reorganization judged by formation of characteristic membrane protrusions in a dose-dependent manner (Fig. 6C). These results therefore indicate that translocation of CRKL to focal adhesions activates pathways toward Rac1 and Cdc42, both of which are necessary for cytoskeletal reorganization.

Among Crk/CrkL SH3 binding proteins, Dock1 (also called Dock180) is an activator of Rac1 (24, 32). Consistent with elevated levels of GTP-loaded Rac1, endogenous Dock1 constitutively localized to focal adhesions in NIH 3T3 cells expressing FA-CRKL (Fig. 6D). On the other hand, overall Rac1 subcellular distribution appeared to be unaffected in these cells (not shown). These results therefore suggest that CrkL translocation leads to Dock1 localization to focal adhesions where Dock1 may activate Rac1.

DISCUSSION

CrkL is a member of the Crk adapter protein family. Crk was originally identified as the cellular homologue of the oncogene product v-Crk in the avian sarcoma virus CT10 (29, 34). Alternative splicing of the cellular *Crk* gene generates two isoforms, Crk-I and Crk-II (also referred to as isoforms a and b),




FIG. 5. FA-CRKL induced cytoskeletal reorganization. (A) Expression of FA-CRKL in NIH 3T3 cells induced multiple membrane protrusions decorated by lamellipodia (arrows). The part highlighted by a white rectangle was enlarged and shown at right. Blue arrowheads indicate FA-CRKL localized to focal adhesions. Green arrowheads indicate FA-CRKL localization at the membrane cortex where F-actin (red arrowheads) also colocalized. Merged color images use red and green to indicate localization of F-actin and FA-CRKL, respectively. (B) Cytoskeletal reorganization induced by transient expression of mutants of FA-CRKL. Localization of F-actin (red) and GFP (green) signals for fusion proteins is shown. Arrowheads indicate membrane protrusions decorated by lamellipodia. (C) Subcellular targeting of CRKL to the outer membrane of mitochondria. Localization of F-actin (red), CRKL-GFP-mito (green), and paxillin (blue) is shown. (D) The incidence of lamellipodial formation was counted after transient expression of each transgene indicated. Percent values indicate the number of NIH 3T3 cells with more than two membrane protrusions decorated by lamellipodia per total transfected (GFP-positive) cells. To assist observation of lamellipodia, cells were stained with phalloidin. Error bars indicate the standard deviation of the sample data collected in three independent sets of samples, each of which was scored with at least 60 cells in random fields under a 40 \times objective lens. (E) The number of protrusions containing lamellipodia per cell (x axis) was counted in each cell and plotted for occurrence (y axis) in NIH 3T3 cells transiently expressing FA-CRKL, FA-CRKL(Δ SH3n), or FA-GFP. For example, four cells had seven lamellipodium-containing protrusions in the FA-CRKL group. A total of 65 cells was counted for each group. Transient expression shown in panels B to E was performed at a dose of 0.1 μ g/well of the expression plasmid, except that the experiments for panel D were performed at a dose of 0.3 μ g/well.

of which Crk-I is structurally more similar to v-Crk, consisting only of one SH2 domain and one SH3 domain (28). Disruption of the Crk-II isoform in mice causes no overt phenotype, while residual transcription from the mutated *Crk* locus generates proteins virtually identical to Crk-I (20). It is therefore possible that either or both Crk-I and CrkL may compensate for loss of the Crk-II isoform in these mice.

Unlike the *Crk* gene, the *Crkl* locus generates only one

protein similar to Crk-II (45). While FA-CRKL was capable of complementing SYF cells in haptotaxis assays, *Crkl*^{-/-} cells showed defects in haptotaxis but not in cell motility stimulated by serum. While it is possible that Crk expressed in *Crkl*^{-/-} cells may partially compensate for CrkL deficiency, it should be noted that *Crkl*^{-/-} cells showed haptotaxis defects despite elevated expression of Crk-II in these cells compared to that in control cells (approximately 1.7-fold compared to that of wild-




FIG. 6. Activation of small G proteins by FA-CRKL. (A) Immunoblot assay for expression levels of FA-CRKL compared to those of endogenous CRKL in NIH 3T3 cells expressing empty vector (CTR; lane 1), FA-CRKL, or FA-CRKL(Δ SH3n). (B) Pull-down assays for GTP-loaded Rac1, Cdc42, and Ras. Overall levels of these small G proteins were determined in parallel by using total cell lysates from NIH 3T3 cells expressing empty vector (CTR; lane 1), FA-CRKL (lane 2), or FA-CRKL(Δ SH3n) (lane 3) (shown at left). GTP-loaded forms were pulled down as described in Materials and Methods, and their levels were determined by immunoblotting by using specific antibodies to these small G proteins (shown at right). Levels of the GTP-loaded form were compared to total levels (not discriminating among GTP- and GDP-bound forms) of the G protein determined in total cell lysates. Experiments were repeated three times and yielded similar results. (C) The effects of dominant-negative forms of small G proteins were evaluated by counting the number of cells that show multiple membrane protrusions induced by FA-CRKL. Increasing doses of expression plasmids for Rac1 N17, Cdc42 N17, RhoA N17, or Ras N17 were cotransfected into NIH 3T3 cells coexpressing FA-CRKL at a fixed dose of 0.1 μ g/well. Cells were stained with phalloidin to aid scoring samples. Values indicate the percentage of cells with lamellipodia among the total number of GFP-positive transfected cells. Error bars indicate the standard deviation of the sample values obtained in three independent sets of samples. (D) Subcellular localization of Dock1 in NIH 3T3 cells that express either FA-CRKL or FA-CRKL(Δ SH3n). Localization of fusion proteins was determined by GFP fluorescence. A part of the FA-CRKL-expressing cell highlighted by the white square was enlarged to show details of colocalization of FA-CRKL with Dock1.

type cells [Fig. 4A]). These results therefore indicate that CrkL plays a specific role in cell migration induced by integrin signaling. However, our results do not exclude the possibility that Crk may function similarly to CrkL in other types of cells or for other purposes. Since CrkL is not essential for serum-stimulated cell motility, it remains to be determined whether serum-stimulated cell migration relies on Crk or on other pathways independent of either Crk or CrkL.

Fak is another protein tyrosine kinase that can directly interact with Src family kinases through the phosphorylated Y397 residue of Fak (40). Fak also associates with the SH3 domain of Cas (31). Like Src family kinases, it has been re-

ported that Fak is also essential for cell motility induced by fibronectin (6, 42). It is worthwhile, however, to note that, although *Fak*^{-/-} cells show impaired chemotaxis toward platelet-derived growth factor, SYF cells are capable of migrating toward this growth factor (25, 43). Therefore, Fak may activate a distinct pathway in addition to those dependent on Src family kinases. It remains to be determined whether CrkL may also play a role in Fak or growth factor-mediated cell motility.

The major Crk/CrkL SH3 binding protein, Dock1, can bind to the small G protein Rac1 (24). Although Dock1 does not have a Dbl homology (DH) domain conserved among conventional guanine nucleotide exchange factors for small G pro-

teins, genetic evidence in *C. elegans* and *Drosophila* suggests that Dock1 (*CED-5* and *Mbc* in worms and flies, respectively) is a critical component of the Rac1 activation machinery (9, 32, 48). It has been reported that Dock1 also contains a PtdIns(3,4,5)P₃ binding site (26). Whereas activated phosphoinositide 3-kinase (PI3K) can induce translocation of endogenous Dock1 to the plasma membrane, it does not increase GTP loading of Rac1 (26). Although "overexpression" of a farnesylated Dock1 mutant has been shown to cause a morphological change (15), these findings suggest that membrane localization of "endogenous" Dock1 per se may not be sufficient for Rac1 activation. On the other hand, expression of FA-CRKL induced cotranslocation of endogenous Dock1 to focal adhesions, which likely explains elevated GTP loading of Rac1 in the cell. It is possible that other pathways that CrkL can mediate may cooperate at focal adhesions for activation of Rac1. In light of the ability of Dock1 to localize to the plasma membrane through the PtdIns(3,4,5)P₃ binding site mentioned above, it is noteworthy that PI3K has been identified as a Crk/CrkL SH3 binding protein (10). Thus, CrkL may affect Dock1 localization not only through its direct binding to Dock1 but also through PI3K. This mechanism may explain the localization of FA-CRKL as well as Dock1 to the leading edge of lamellipodia in addition to focal adhesions. Interestingly, despite the ability of Dock1 to associate with Rac1, subcellular distribution of Rac1 was not overtly different between FA-CRKL-expressing cells and their controls (not shown). Therefore, activation of Dock1 and other cofactors may be an important mechanism for Rac1 activation rather than Rac1 translocation.

Recently, it was shown that complex formation between Dock1 and ELMO1 is also necessary for Rac1 activation (4). Genetic evidence from *C. elegans* suggests an essential role for the pathway of CED-2 (Crk-II), CED-5 (Dock1), and CED-12 (ELMO) to CED-10 (Rac) activation in cell migration as well as engulfment of apoptotic bodies (11, 49, 50). However, involvement of Src-like kinases or Cas in this pathway has not been reported in *C. elegans*. Furthermore, although Crk-II has been referred to as the CED-2 orthologue (33), our TBLASTN search of the WormBase (Sanger Institute) indicates that amino acid sequence similarities between mouse CrkL and CED-2 are comparable to those of mouse Crk-II and CED-2 (52 versus 62%), while the smallest-sum probability was 2.4×10^{-8} versus 1.9×10^{-6} , respectively. Therefore, it is tempting to speculate that, in cells of higher organisms such as mammals in which Crk and CrkL genes are evolved from the common ancestral gene CED-2, CrkL specifically links integrin signaling to this evolutionally conserved pathway downstream of Src and Cas.

While cotranslocation of CrkL and Dock1 to focal adhesions likely explains the mechanism of Rac1 activation, FA-CRKL-induced GTP loading of Cdc42 may involve other mechanisms. It has been reported that Dock1 can activate Rac1 but not Cdc42 in 293T cells (24). It is possible that Cdc42 may be activated by a pathway downstream of Rac1 in embryonic fibroblasts. However, it should be noted that Rac1 and Cdc42 appear to be activated in distinct spatiotemporal patterns in randomly moving HT1080 cells (22). It is not yet clear whether the latter observation can be generalized to other cell types such as MEFs or to cells undergoing integrin-induced direc-

tional migration. The mechanisms by which CrkL activates Cdc42 remain to be determined.

Since paxillin is a major component of focal adhesions and is required for general cell motility (13), it is possible that FA-CRKL fusion proteins may influence cell signaling independent of CRKL either by activating LIM domain-dependent functions or by replacing endogenous paxillin from focal adhesions. In addition, one might anticipate that FA-CRKL(Δ SH3n) potentially acts as a dominant-negative protein. However, FA-GFP (fusion of GFP and paxillin LIM domains) or FA-CRKL(Δ SH3n) did not affect the cell morphology or the ability of the cell to migrate toward fibronectin or serum. Also, NIH 3T3 cells expressing a similar fusion of CRKL with the FAT domain of Fak showed cell morphology indistinguishable from that of FA-CRKL (not shown). These observations therefore suggest that these possibilities mentioned above are unlikely at least under the experimental conditions used in our studies, although it is difficult to completely rule them out.

Crkl^{-/-} embryos show developmental defects in migratory stem cell-like populations called neural crest cells in which integrin signaling presumably plays an important role. Our findings in *Crkl*^{-/-} MEFs may therefore help to explain the phenotype of CrkL-deficient mice. Mouse embryos lacking Src, Fyn, and Yes show a severe phenotype (25) at embryonic day 9.5. Mice lacking Crkas (mouse Cas) die around embryonic day 12.5 due likely to heart failure (19). Since these phenotypes are severer than that of *Crkl*^{-/-} embryos, it is likely that pathways dependent on CrkL may not represent all signaling pathways that Src family kinases mediate through Cas. Functional and genetic links between *Crkl* and *Crkas* as well as *Src* family members remain to be established in order to determine the molecular mechanism of the *Crkl*^{-/-} mutant phenotype in vivo.

ACKNOWLEDGMENTS

We thank S. Kron for critical reading of the manuscript; B. J. Druker, F. B. Gertler, H. Hirai, M. Matsuda, G. P. Nolan, S. M. Thomas, M. A. Schwartz, and P. Soriano for valuable reagents; and S. Bond for technical assistance at the University of Chicago Digital Microscopy Facility.

This work was supported in part by grants to A.I. from Wendy Will Case Cancer Fund, the American Cancer Society (RPG 00-239-01-CSM), and Department of the Army (DAMD 17-02-1-0639).

REFERENCES

- Anderson, S. M., E. A. Burton, and B. L. Koch. 1997. Phosphorylation of Cbl following stimulation with interleukin-3 and its association with Grb2, Fyn, and phosphatidylinositol 3-kinase. *J. Biol. Chem.* 272:739-745.
- Bear, J. E., J. J. Loureiro, I. Libova, R. Fassler, J. Wehland, and F. B. Gertler. 2000. Negative regulation of fibroblast motility by Ena/VASP proteins. *Cell* 101:717-728.
- Brown, M. C., J. A. Perrotta, and C. E. Turner. 1996. Identification of LIM3 as the principal determinant of paxillin focal adhesion localization and characterization of a novel motif on paxillin directing vinculin and focal adhesion kinase binding. *J. Cell Biol.* 135:1109-1123.
- Brugnera, E., L. Haney, C. Grimsley, M. Lu, S. F. Walk, A. C. Tosello-Trampont, I. G. Macara, H. Madhani, G. R. Fink, and K. S. Ravichandran. 2002. Unconventional Rac-GEF activity is mediated through the Dock180 ELMO complex. *Nat. Cell Biol.* 4:574-582.
- Butler, A. A., V. A. Blakesley, A. Koval, R. deJong, J. Groffen, and D. Le Roith. 1997. *In vivo* regulation of CrkII and CrkL proto-oncogenes in the uterus by insulin-like growth factor-I. Differential effects on tyrosine phosphorylation and association with paxillin. *J. Biol. Chem.* 272:27660-27664.
- Cary, L. A., D. C. Han, T. R. Polte, S. K. Hanks, and J. L. Guan. 1998. Identification of p130Cas as a mediator of focal adhesion kinase-promoted cell migration. *J. Cell Biol.* 140:211-221.

7. Cary, L. A., R. A. Klinghoffer, C. Sachsenmaier, and J. A. Cooper. 2002. SRC catalytic but not scaffolding function is needed for integrin-regulated tyrosine phosphorylation, cell migration, and cell spreading. *Mol. Cell. Biol.* 22:2427–2440.
8. Donaldson, L. W., G. Gish, T. Pawson, L. E. Kay, and J. D. Forman-Kay. 2002. Structure of a regulatory complex involving the Abl SH3 domain, the Crk SH2 domain, and a Crk-derived phosphopeptide. *Proc. Natl. Acad. Sci. USA* 99:14053–14058.
9. Erickson, M. R., B. J. Galletta, and S. M. Abmayr. 1997. *Drosophila* myoblast city encodes a conserved protein that is essential for myoblast fusion, dorsal closure, and cytoskeletal organization. *J. Cell Biol.* 138:589–603.
10. Feller, S. M. 2001. Crk family adaptors—signalling complex formation and biological roles. *Oncogene* 20:6348–6371.
11. Gumienny, T. L., E. Brugnera, A. C. Tosello-Trampont, J. M. Kinchen, L. B. Haney, K. Nishiwaki, S. F. Walk, M. E. Nemergut, I. G. Macara, R. Francis, T. Schedl, Y. Qin, L. Van Aelst, M. O. Hengartner, and K. S. Ravichandran. 2001. CED-12/ELMO, a novel member of the CrkII/Dock180/Rac pathway, is required for phagocytosis and cell migration. *Cell* 107:27–41.
12. Guris, D. L., J. Fantes, D. Tara, B. J. Druker, and A. Imamoto. 2001. Mice lacking the homologue of the human 22q11.2 gene *CRKL* phenocopy neurocristopathies of DiGeorge syndrome. *Nat. Genet.* 27:293–298.
13. Hagel, M., E. L. George, A. Kim, R. Tamimi, S. L. Opitz, C. E. Turner, A. Imamoto, and S. M. Thomas. 2002. The adaptor protein paxillin is essential for normal development in the mouse and is a critical transducer of fibronectin signaling. *Mol. Cell. Biol.* 22:901–915.
14. Hamasaki, K., T. Mimura, N. Morino, H. Furuya, T. Nakamoto, S. Aizawa, C. Morimoto, Y. Yazaki, H. Hirai, and Y. Nojima. 1996. Src kinase plays an essential role in integrin-mediated tyrosine phosphorylation of Crk-associated substrate p130Cas. *Biochem. Biophys. Res. Commun.* 222:338–343.
15. Hasegawa, H., E. Kiyokawa, S. Tanaka, K. Nagashima, N. Gotoh, M. Shibuya, T. Kurata, and M. Matsuda. 1996. DOCK180, a major CRK-binding protein, alters cell morphology upon translocation to the cell membrane. *Mol. Cell. Biol.* 16:1770–1776.
16. Heaney, C., K. Kolibaba, A. Bhat, T. Oda, S. Ohno, S. Fanning, and B. J. Druker. 1997. Direct binding of CRKL to BCR-ABL is not required for BCR-ABL transformation. *Blood* 89:297–306.
17. Hemmeryckx, B., A. van Wijk, A. Reichert, V. Kaartinen, R. de Jong, P. K. Pattengale, I. Gonzalez-Gomez, J. Groffen, and N. Heisterkamp. 2001. Crkl enhances leukemogenesis in BCR/ABL P190 transgenic mice. *Cancer Res.* 61:1398–1405.
18. Honda, H., T. Nakamoto, R. Sakai, and H. Hirai. 1999. p130(Cas), an assembling molecule of actin filaments, promotes cell movement, cell migration, and cell spreading in fibroblasts. *Biochem. Biophys. Res. Commun.* 262:25–30.
19. Honda, H., H. Oda, T. Nakamoto, Z. Honda, R. Sakai, T. Suzuki, T. Saito, K. Nakamura, K. Nakao, T. Ishikawa, M. Katsuki, Y. Yazaki, and H. Hirai. 1998. Cardiovascular anomaly, impaired actin bundling and resistance to Src-induced transformation in mice lacking p130Cas. *Nat. Genet.* 19:361–365.
20. Imaizumi, T., K. Araki, K. Miura, M. Araki, M. Suzuki, H. Terasaki, and K. Yamamura. 1999. Mutant mice lacking Crk-II caused by the gene trap insertional mutagenesis: Crk-II is not essential for embryonic development. *Biochem. Biophys. Res. Commun.* 266:569–574.
21. Imamoto, A., and P. Soriano. 1993. Disruption of the *csk* gene, encoding a negative regulator of Src family tyrosine kinases, leads to neural tube defects and embryonic lethality in mice. *Cell* 73:1117–1124.
22. Itoh, R. E., K. Kurokawa, Y. Ohba, H. Yoshizaki, N. Mochizuki, and M. Matsuda. 2002. Activation of Rac and Cdc42 video imaged by fluorescent resonance energy transfer-based single-molecule probes in the membrane of living cells. *Mol. Cell. Biol.* 22:6582–6591.
23. Kinsella, T. M., and G. P. Nolan. 1996. Episomal vectors rapidly and stably produce high-titer recombinant retrovirus. *Hum. Gene Ther.* 7:1405–1413.
24. Kiyokawa, E., Y. Hashimoto, S. Kobayashi, H. Sugimura, T. Kurata, and M. Matsuda. 1998. Activation of Rac1 by a Crk SH3-binding protein, DOCK180. *Genes Dev.* 12:3331–3336.
25. Klinghoffer, R. A., C. Sachsenmaier, J. A. Cooper, and P. Soriano. 1999. Src family kinases are required for integrin but not PDGFR signal transduction. *EMBO J.* 18:2459–2471.
26. Kobayashi, S., T. Shirai, E. Kiyokawa, N. Mochizuki, M. Matsuda, and Y. Fukui. 2001. Membrane recruitment of DOCK180 by binding to PtdIns(3,4,5)P₃. *Biochem. J.* 354:73–78.
27. Li, L., M. Okura, and A. Imamoto. 2002. Focal adhesions require catalytic activity of Src family kinases to mediate integrin-matrix adhesion. *Mol. Cell. Biol.* 22:1203–1217.
28. Matsuda, M., S. Tanaka, S. Nagata, A. Kojima, T. Kurata, and M. Shibuya. 1992. Two species of human *CRK* cDNA encode proteins with distinct biological activities. *Mol. Cell. Biol.* 12:3482–3489.
29. Mayer, B. J., M. Hamaguchi, and H. Hanafusa. 1988. A novel viral oncogene with structural similarity to phospholipase C. *Nature* 332:272–275.
30. Morgenstern, J. P., and H. Land. 1990. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. *Nucleic Acids Res.* 18:3587–3596.
31. Nakamoto, T., R. Sakai, H. Honda, S. Ogawa, H. Ueno, T. Suzuki, S.-I. Aizawa, Y. Yazaki, and H. Hirai. 1997. Requirements for localization of p130^{cas} to focal adhesions. *Mol. Cell. Biol.* 17:3884–3897.
32. Nolan, K. M., K. Barrett, Y. Lu, K. Q. Hu, S. Vincent, and J. Settleman. 1998. Myoblast city, the *Drosophila* homolog of DOCK180/CED-5, is required in a Rac signaling pathway utilized for multiple developmental processes. *Genes Dev.* 12:3337–3342.
33. Reddien, P. W., and H. R. Horvitz. 2000. CED-2/CrkII and CED-10/Rac control phagocytosis and cell migration in *Caenorhabditis elegans*. *Nat. Cell Biol.* 2:131–136.
34. Reichman, C. T., B. J. Mayer, S. Keshav, and H. Hanafusa. 1992. The product of the cellular *crk* gene consists primarily of SH2 and SH3 regions. *Cell Growth Differ.* 3:451–460.
35. Ruest, P. J., N.-Y. Shin, T. R. Polte, X. Zhang, and S. K. Hanks. 2001. Mechanisms of CAS substrate domain tyrosine phosphorylation by FAK and Src. *Mol. Cell. Biol.* 21:7641–7652.
36. Sakai, R., A. Iwamatsu, N. Hirano, S. Ogawa, T. Tanaka, H. Mano, Y. Yazaki, and H. Hirai. 1994. A novel signaling molecule, p130, forms stable complexes in vivo with v-Crk and v-Src in a tyrosine phosphorylation-dependent manner. *EMBO J.* 13:3748–3756.
37. Sakai, R., T. Nakamoto, K. Ozawa, S. Aizawa, and H. Hirai. 1997. Characterization of the kinase activity essential for tyrosine phosphorylation of p130Cas in fibroblasts. *Oncogene* 14:1419–1426.
38. Salgia, R., E. Pisick, M. Sattler, J. L. Li, N. Uemura, W. K. Wong, S. A. Burky, H. Hirai, L. B. Chen, and J. D. Griffin. 1996. p130CAS forms a signaling complex with the adapter protein CRKL in hematopoietic cells transformed by the BCR/ABL oncogene. *J. Biol. Chem.* 271:25198–25203.
39. Salgia, R., N. Uemura, K. Okuda, J. L. Li, E. Pisick, M. Sattler, R. de Jong, B. Druker, N. Heisterkamp, L. B. Chen, et al. 1995. CRKL links p210BCR/ABL with paxillin in chronic myelogenous leukemia cells. *J. Biol. Chem.* 270:29145–29150.
40. Schaller, M. D., J. D. Hildebrand, J. D. Shannon, J. W. Fox, R. R. Vines, and J. T. Parsons. 1994. Autophosphorylation of the focal adhesion kinase, pp125^{FAK}, directs SH2-dependent binding of pp60^{src}. *Mol. Cell. Biol.* 14:1680–1688.
41. Senechal, K., C. Heaney, B. Druker, and C. L. Sawyers. 1998. Structural requirements for function of the Crkl adapter protein in fibroblasts and hematopoietic cells. *Mol. Cell. Biol.* 18:5082–5090.
42. Sieg, D. J. 1999. Required role of focal adhesion kinase (FAK) for integrin-stimulated cell migration. *J. Cell Sci.* 112:2677–2691.
43. Sieg, D. J., C. R. Hauck, D. Ilic, C. K. Klingbeil, E. Schaefer, C. H. Damsky, and D. D. Schlaepfer. 2000. FAK integrates growth-factor and integrin signals to promote cell migration. *Nat. Cell Biol.* 2:249–256.
44. Tachibana, K., T. Urano, H. Fujita, Y. Ohashi, K. Kamiguchi, S. Iwata, H. Hirai, and C. Morimoto. 1997. Tyrosine phosphorylation of Crk-associated substrates by focal adhesion kinase. A putative mechanism for the integrin-mediated tyrosine phosphorylation of Crk-associated substrates. *J. Biol. Chem.* 272:29083–29090.
45. ten Hoeve, J., C. Morris, N. Heisterkamp, and J. Groffen. 1993. Isolation and chromosomal localization of *CRKL*, a human *crk-like* gene. *Oncogene* 8:2469–2474.
46. Thomas, S. M., P. Soriano, and A. Imamoto. 1995. Specific and redundant roles of Src and Fyn in organizing the cytoskeleton. *Nature* 376:267–271.
47. Vuori, K., H. Hirai, S. Aizawa, and E. Ruoslahti. 1996. Introduction of p130^{cas} signaling complex formation upon integrin-mediated cell adhesion: a role for Src family kinases. *Mol. Cell. Biol.* 16:2606–2613.
48. Wu, Y. C., and H. R. Horvitz. 1998. *C. elegans* phagocytosis and cell-migration protein CED-5 is similar to human DOCK180. *Nature* 392:501–504.
49. Wu, Y. C., M. C. Tsai, L. C. Cheng, C. J. Chou, and N. Y. Weng. 2001. *C. elegans* CED-12 acts in the conserved crkII/DOCK180/Rac pathway to control cell migration and cell corpse engulfment. *Dev. Cell* 1:491–502.
50. Zhou, Z., E. Caron, E. Hartwig, A. Hall, and H. R. Horvitz. 2001. The *C. elegans* PH domain protein CED-12 regulates cytoskeletal reorganization via a Rho/Rac GTPase signaling pathway. *Dev. Cell* 1:477–489.
51. Zwartkruis, F. J., R. M. Wolthuis, N. M. Nabben, B. Franke, and J. L. Bos. 1998. Extracellular signal-regulated activation of Rap1 fails to interfere in Ras effector signalling. *EMBO J.* 17:5905–5912.